Senju Pharmaceutical
3-1-9, Kawara-machi, Chuo-ku, Osaka, 541-0048, Japan
Overview
Senju Pharmaceutical produces ophthalmic medicine, prescription drugs, and over the counter medicines. Senju Pharmaceutical, as a pioneer of ophthalmic medicine, has always been on the path of originality as a pioneer of ophthalmic medicine under the development policy of giving priority to safety and the sense of mission to serve the eye health of people all over the world. It aims to create excellent medicines and services in the areas of the five senses (visual, auditory, olfactory, taste, and tactile) that are sensor functions that make people feel the joy of living.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Semathera
Led · Equity · Mar 2018
SemaThera is a Montreal-based biotech developing novel anti-SEMA3A therapies for the treatment of several retinopathies. Its lead candidate, ST-102, is a bispecific biological trap that inhibits semaphorin 3A (SEMA3A) and vascular endothelial growth factor (VEGF). The company is preparing ST-102 for a clinical trial application in diabetic macular edema (DME). SemaThera closed a $2M co-investment from Senju Pharmaceutical and AmorChem and signed an exclusive option to license ST-102 in China and Japan with Senju. Under the option Senju would assume all clinical development costs and regulatory fees in China and Japan, pay milestone payments totaling in the eight-digit range, and provide a two-digit percent royalty on sales; Senju also holds exclusive rights to other indications in those territories. The company appointed John G. Clement, Ph.D., as Executive Vice‑President, Business Development, and its SEMA3A-based technologies may have future applications in cancer and neurodegenerative diseases.
Team
No current team members are available.